RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma by Sara Egea‐Rodriguez, Renáta Váraljai, Thierry M. Nordmann, Restuan Lubis, Manuel Philip, Florian Rambow, Alexander Roesch, Michael Flaig, Susanne Horn, Raphael Stoll, Fang Zhao, Annette Paschen, Bert Klebl, Ian D. Hickson, Dirk Schadendorf, Matthias Mann, Iris Helfrich

Subjects: Get full text

Erratum to “Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis” by Laura Ridolfi, Massimiliano Petrini, Laura Fiammenghi, Anna Maria Granato, Valentina Ancarani, Elena Pancisi, Emanuela Scarpi, Massimo Guidoboni, Giuseppe Migliori, Stefano Sanna, Francesca Tauceri, Giorgio Maria Verdecchia, Angela Riccobon, Linda Valmorri, Ruggero Ridolfi

Get full text

TCF1-positive and TCF1-negative TRM CD8 T cell subsets and cDC1s orchestrate melanoma protection and immunotherapy response by Saraí G De León-Rodríguez, Cristina Aguilar-Flores, Julián A Gajón, Ángel Juárez-Flores, Alejandra Mantilla, Raquel Gerson-Cwilich, José Fabián Martínez-Herrera, Diana Alejandra Villegas-Osorno, Claudia T Gutiérrez-Quiroz, Sergio Buenaventura-Cisneros, Mario Alberto Sánchez-Prieto, Edmundo Castelán-Maldonado, Samuel Rivera Rivera, Ezequiel M Fuentes-Pananá, Laura C Bonifaz

“…Background Melanoma, the most lethal form of skin cancer, has undergone a transformative treatment shift with the advent of checkpoint blockade immunotherapy (CBI). …”
Get full text

Epidemiological profile and clinical characteristics of ocular and periocular tumors in North and Central India by Chhavi Gupta, Narendra Patidar, Himanshu Gaikwad, Mihir Mishra, Sima Das

Subjects: Get full text

The effects of tumor-derived exosomes enriched with miRNA-211a on B16F10 cells by Mohammad Reza Atashzar, Mohammad Reza Ataollahi, Ali Ghanbari Asad, Parisa Doroudgar, Davar Amani

Subjects: Get full text

Ruthenium(II) Complex with 1-Hydroxy-9,10-Anthraquinone Inhibits Cell Cycle Progression at G0/G1 and Induces Apoptosis in Melanoma Cells by Júlia S. M. Dias, Guilherme A. Ferreira-Silva, Rommel B. Viana, João H. de Araujo Neto, Javier Ellena, Rodrigo S. Corrêa, Marília I. F. Barbosa, Marisa Ionta, Antônio C. Doriguetto

Subjects: Get full text

Papel de la Farmacia Comunitaria en la Prevención Secundaria del Cáncer de Piel by Augusto González Borrego, María Reyes Jiménez Blanco

Subjects: “…melanoma…”
Get full text

Membrane Bound CRT Fragment Accelerates Tumor Growth of Melanoma B16 Cell In Vivo through Promoting M2 Polarization via TLR4 by Hong-Min Wang, Zhe Zhou, Jie Miao, Bo Zhu, Xiao-Qiu Dai, Qiao Zhong, Fang-Yuan Gong, Xiao-Ming Gao

“…Here, we constructed stable B16 melanoma cell lines expressing recombinant CRT/39-272 on the membrane (B16-tmCRT/39-272) to investigate the roles of cell surface CRT on tumor progression. …”
Get full text

TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune Targets by Trudy Straetemans, Mandy van Brakel, Sabine van Steenbergen, Marieke Broertjes, Joost Drexhage, Joost Hegmans, Bart N. Lambrecht, Cor Lamers, Pierre van Der Bruggen, Pierre G. Coulie, Reno Debets

“…We molecularly characterized TCRαβ genes of an MC2/A2-specific CD8 and MA3/DP4-specific CD4 T-cell clone derived from melanoma patients who responded clinically to MAGE vaccination. …”
Get full text

Nonlethal Levels of Zeaxanthin Inhibit Cell Migration, Invasion, and Secretion of MMP-2 via NF-κB Pathway in Cultured Human Uveal Melanoma Cells by Ming-Chao Bi, Nicole Hose, Cai-Lian Xu, Chen Zhang, Jodi Sassoon, E. Song

“…Zeaxanthin at nonlethal dosages (3–10 μM) significantly inhibited the cell migration of cultured uveal melanoma cells (C918 cell line) as determined by wound healing assay and Boyden chamber assay. …”
Get full text

Exploring the Impact of the Multimodal CAPABLE eHealth Intervention on Health-Related Quality of Life in Patients With Melanoma Undergoing Immune-Checkpoint Inhibition: Prospective Pilot Study by Itske Fraterman, Lucia Sacchi, Henk Mallo, Valentina Tibollo, Savannah Lucia Catherina Glaser, Stephanie Medlock, Ronald Cornet, Matteo Gabetta, Vitali Hisko, Vadzim Khadakou, Ella Barkan, Laura Del Campo, David Glasspool, Alexandra Kogan, Giordano Lanzola, Roy Leizer, Manuel Ottaviano, Mor Peleg, Konrad Śniatała, Aneta Lisowska, Szymon Wilk, Enea Parimbelli, Silvana Quaglini, Mimma Rizzo, Laura Deborah Locati, Annelies Boekhout, Lonneke V van de Poll-Franse, Sofie Wilgenhof

“… Abstract BackgroundPatients with melanoma receiving immunotherapy with immune-checkpoint inhibitors often experience immune-related adverse events, cancer-related fatigue, and emotional distress, affecting health-related quality of life () and clinical outcome to immunotherapy. eHealth tools can aid patients with cancer in addressing issues, such as adverse events and psychosocial well-being, from various perspectives. …”
Get full text

Influence of urokinase gene-knockout in C57BL/6-PlautmI. IBugThisPlau6FDhu/GFDhu mice on growth factors in malignant melanoma by E. M. Frantsiyants, I. V. Kaplieva, I. V. Neskubina, V. A. Bandovkina, L. K. Trepitaki, E. I. Surikova, N. D. Cheryarina, L. A. Nemashkalova, N. S. Lesovaya

Subjects: Get full text

Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma by Mahdieh Fazel, Patrick M. Jedlowski

“…Immune checkpoint inhibitors targeting programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 have improved survival in patients with metastatic melanoma, especially in combination (i.e., ipilimumab-nivolumab). …”
Get full text

Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis by Konstantinos Lallas, Eftychia Chatziioannou, Derya Durak, Georg Frey, Lina Maria Serna-Higuita, Marie-Lena Rasch, Athanassios Kyrgidis, Eleni Timotheadou, Zoe Apalla, Ulrike Leiter, Lukas Flatz, Lukas Flatz, Aimilios Lallas, Teresa Amaral, Teresa Amaral

Subjects: Get full text

Comparison between 18F-Fluorodeoxyglucose Positron Emission Tomography and Sentinel Lymph Node Biopsy for Regional Lymph Nodal Staging in Patients with Melanoma: A Review of the Literature by Paoletta Mirk, Giorgio Treglia, Marco Salsano, Pietro Basile, Alessandro Giordano, Lorenzo Bonomo

“…Aim. to compare 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) to sentinel lymph node biopsy (SLNB) for regional lymph nodal staging in patients with melanoma. Methods. We performed a literature review discussing original articles which compared FDG-PET to SLNB for regional lymph nodal staging in patients with melanoma. …”
Get full text

Clinical characteristics, therapeutics, and treatment outcomes of adult patients with anti-melanoma differentiation-associated gene 5 dermatomyositis: A single-center experience from South India by Shivraj Padiyar, Aswin M Nair, Bijesh Yadav, Prathyusha Manikuppam, Jha Avanish, Abhilasha Arvind Manwatkar, John Mathew

Subjects: “…anti-melanoma differentiation-associated gene 5…”
Get full text

Sinonasal malignancies: histopathological entities, regional involvement and long-term outcome by Lukas Anschuetz, Ralph Hohenberger, Christoph Kaecker, Olgun Elicin, Roland Giger, Marco Caversaccio

Subjects: Get full text

RATIONAL DRUG DESIGN OF POTENT V600E-BRAF KINASE INHIBITORS THROUGH MOLECULAR DOCKING SIMULATION by Bello Abdullahi Umar, Adamu Uzairu, Gideion Adamu Shallangwa, Sani Uba

Subjects: “…Melanoma…”
Get full text

Reconstruction of a Large Groin Defect using Pedicled Chimeric Tensor Fascia Lata and Vastus Lateralis Muscle Flaps Following Malignant Melanoma Excision: A Case Report by Archita N Rai, Swati Deshpande, Firoz Borle, Raju Shinde, Aditya Kale

“…A 68-year-old male, previously treated for melanoma of the left foot, presented with a recurrent swelling in the left inguinal region. …”
Get full text

Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma by Lucie Heinzerling, Michael Fluck, Caroline Robert, Celeste Lebbe, Erika Richtig, Sven D Koch, Ulrike Gnad-Vogt, Tobias Seibel, Thomas Eigentler, Juan Martin-Liberal, Sebastian Ochsenreither, Peter Mohr, Patrick Terheyden, Carsten Weishaupt, Michael Erdmann, Lukas Koch, Ainara Soria, Igor Samoylenko, Jürgen Krauß, Peter Brossart, Franz Georg Bauernfeind, Marina Gonzalez, Peter Wengenmayer, Ioannis Thomas, Artem Poltoratskiy, Marina Sekacheva, Beate Schmitt-Bormann, Gianluca Quintini, Martin Falk, Paula Codó, Arjun Oberoi, Jana Hess, Yulia Semiletova, Casilda Llacer Perez, Oliver Schönborn-Kellenberger

“…In the expansion cohorts in patients with anti-PD-1 therapy-refractory melanoma, 0/10 patients treated with CV8102 as monotherapy and 5/30 patients (17%) treated in combination with a PD-1 inhibitor experienced objective responses.Conclusions IT CV8102 was generally well tolerated with preliminary signs of efficacy as monotherapy and in combination with a PD-1 inhibitor.Trial registration number NCT03291002.…”
Get full text